Vitiligo - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 57 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vitiligo - Pipeline Review, H2 2016, provides an overview of the Vitiligo (Dermatology) pipeline landscape.

Vitiligo is a condition in which skin loses melanin, the pigment that determines the color of skin, hair and eyes. Symptoms include premature whitening or graying of the hair on scalp, eyelashes, eyebrows or beard, loss of color in the tissues that line the inside of mouth and loss of or change in color of the inner layer of eye. Treatment includes corticosteroid therapy, immunomodulators and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vitiligo - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Vitiligo (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vitiligo (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Vitiligo and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 2 respectively for Vitiligo.

Vitiligo (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Vitiligo (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Vitiligo (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Vitiligo (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Vitiligo (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Vitiligo (Dermatology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Vitiligo (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Vitiligo (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Vitiligo Overview 6
Therapeutics Development 7
Pipeline Products for Vitiligo - Overview 7
Vitiligo - Therapeutics under Development by Companies 8
Vitiligo - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Vitiligo - Products under Development by Companies 11
Vitiligo - Companies Involved in Therapeutics Development 12
Ache Laboratorios Farmaceuticos S/A 12
Biocon Limited 13
Bristol-Myers Squibb Company 14
Clinuvel Pharmaceuticals Limited 15
Vitiligo - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
abatacept - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
ACH-24 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
afamelanotide - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
itolizumab - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
VLRX-001 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Vitiligo - Dormant Projects 42
Vitiligo - Product Development Milestones 43
Featured News & Press Releases 43
Dec 03, 2015: Positive preliminary results in Singaporean vitiligo study 43
Dec 03, 2015: Update on North American vitiligo program for SCENESSE 44
May 05, 2015: Clinuvel announces innovative melanocortin for new indications 45
Mar 20, 2015: SCENESSE vitiligo data presented at world's largest dermatology conference 46
Sep 19, 2014: SCENESSE vitiligo study results published in JAMA Dermatology 47
May 06, 2014: Clinuvel's Phase II vitiligo study commences in Singapore 48
Mar 20, 2014: SCENESSE data to feature at American Academy of Dermatology 48
Nov 04, 2013: Clinuvel to start a Phase II vitiligo study in Singapore 49
Sep 02, 2013: Five month study follow up shows SCENESSE combination treatment provided stable repigmentation in vitiligo patients 50
Mar 01, 2013: SCENESSE data to be presented at American Academy of Dermatology, San Gallicano Rare Disease conference 51
Dec 19, 2012: Clinuvel Pharma Announces Results From Phase IIa Pilot Study Of Scenesse In Vitiligo 51
Oct 16, 2012: Observations from Clinuvels US vitiligo study published 53
Mar 15, 2012: Observations from Clinuvels vitiligo and EPP programs being presented at the 53
Mar 02, 2011: Clinuvel Announces FDA Approval For Vitiligo Drug Trial 54
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 56
Disclaimer 57

List of Tables

Number of Products under Development for Vitiligo, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Comparative Analysis by Early Stage Development, H2 2016 10
Products under Development by Companies, H2 2016 11
Vitiligo - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016 12
Vitiligo - Pipeline by Biocon Limited, H2 2016 13
Vitiligo - Pipeline by Bristol-Myers Squibb Company, H2 2016 14
Vitiligo - Pipeline by Clinuvel Pharmaceuticals Limited, H2 2016 15
Assessment by Monotherapy Products, H2 2016 16
Number of Products by Stage and Target, H2 2016 18
Number of Products by Stage and Mechanism of Action, H2 2016 20
Number of Products by Stage and Route of Administration, H2 2016 22
Number of Products by Stage and Molecule Type, H2 2016 24
Vitiligo - Dormant Projects, H2 2016 42